Apitope Announces Management Changes

Keith Martin to retire as CEO, continue as Non-Executive DirectorHayley French appointed COO and interim CEO
HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer (CEO) Dr Keith Martin has decided to retire from the CEO role after 12 years at the helm of Apitope. He will remain on the Apitope Board as a non-executive director. Dr Hayley French will move to Chief Operations Officer (COO) and act as interim CEO of Apitope until a permanent replacement is in place. Dr French will join the Board of Directors effective immediately.

Dr French brings over 25 years of experience in the pharmaceutical and biotechnology industry, most recently as Chief Business Officer & General Counsel of Apitope and prior to this she spent three years at Novartis where she worked on all global deals and collaborations in the respiratory division. She has been with Apitope since November 2010 and has over twenty years’ experience of negotiating licences and collaborations and managing alliances in the life sciences sector.

Stéphane Verdood, Chairman of the Board of Directors of Apitope, commented: “Keith’s contribution to Apitope’s growth during his 12-year tenure has been immeasurable. Under his strategic leadership Apitope has grown to be a clinical stage biotech with multiple programmes in development for diseases with high unmet needs. On behalf of the Board we would like to thank Keith for his contribution to Apitope and we are delighted he will stay on the Board as a Non-executive Director.

“I am very pleased that Hayley has agreed to take on the role of COO and interim CEO to ensure the smooth running of the company. She has played a major role in Apitope’s growth and success over the past eight years and the Board is confident in her expertise and experience in progressing Apitope’s growth and maximising the potential of its clinical programmes.”

Dr Keith Martin said: “It has been an honour to have led Apitope and the transformation of the company from a University of Bristol spin-out to a clinical stage company with a strong clinical pipeline. I am proud of our achievements to date and I look forward to supporting the growth and development of Apitope as a Board member.”

Dr Hayley French, newly appointed interim CEO of Apitope, added: ” With efficacy demonstrated in two diseases, Apitope has a robust clinical pipeline of first-in-class antigen-specific immunotherapies for the treatment of autoimmune diseases. Apitope’s ATX-MS-1467 is a potential game changer in the treatment of multiple sclerosis and ATX-GD-59 appears to be the first disease-modifying treatment for Graves’ disease in over 60 years. I look forward to maximising the potential of these important new treatments and lead the Company through its next phase of growth.”

Prior to joining Apitope, Dr French spent three years at Novartis and prior to this worked in the Life Sciences Group of Bird & Bird, London, specialising in advising pharmaceutical and biotech companies. Prior to joining Bird & Bird, she was Head of Commercial Legal Affairs at the Centre for Applied Microbiology and Research (CAMR) in Salisbury, UK. Dr French started her career at University College London Ventures where she was responsible for the development, management and commercialisation of technologies in the life sciences sector. She is past president of the Licensing Executives Society Britain & Ireland, and chair of the Licensing Executives Society International (LESI) life sciences committee.

Dr French teaches on the LESI Intellectual Asset Management courses and is a regular speaker on IP licensing and negotiation. She has a B.Sc. in Microbiology from the University of Liverpool, as well as a PhD in Microbiology and a M.Sc. in intellectual property from the University of London and is a certified licensing professional (CLP).